Status:
COMPLETED
A Study of LY3375880 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate how well LY3375880 (study drug) is tolerated in healthy participants and what side effects may occur. The study drug will be administered either subcutaneously...
Eligibility Criteria
Inclusion
- Are overtly healthy males or females, as determined by medical history and physical examination
- Have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m²) inclusive
- Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Exclusion
- Have known allergies to LY3375880, related compounds or any components of the formulation, or history of significant atopy
- Are women who are of childbearing potential or who are lactating
Key Trial Info
Start Date :
November 17 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 16 2018
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03343587
Start Date
November 17 2017
End Date
November 16 2018
Last Update
December 10 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Parexel Early Phase Unit at Glendale
Glendale, California, United States, 91206